Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 389

Sort by

Sort Order Select

Journal Articles

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Mun Yee Koh, Tae-Hoon Chung, Nicole Xin Ning Tang, Sabrina Hui Min Toh, Jianbiao Zhou, Tze King Tan, Leilei Chen, Wee Joo Chng, Phaik Ju Teoh

Blood (2025) 145 (11): 1164–1181.

https://doi.org/10.1182/blood.2024024429

Published: 2025

Includes: Supplemental data

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don Benson, Maria Chaudry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2025) 145 (9): 944–955.

https://doi.org/10.1182/blood.2024026124

Published: 2025

Includes: Supplemental data

Journal Articles

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Blood (2025) 145 (9): 970–974.

https://doi.org/10.1182/blood.2024025624

Published: 2025

Includes: Supplemental data

Journal Articles

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Blood (2025) 145 (7): 732–747.

https://doi.org/10.1182/blood.2024025690

Published: 2025

Includes: Supplemental data

Journal Articles

Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma

Daisuke Ikeda, Shuichi Aikawa, Chiho Misono, Mitsuaki Oura, Fuminari Fujii, Hajime Sakuma, Masanori Toho, Atsushi Uehara, Rikako Tabata, Kentaro Narita, Masami Takeuchi, Tomohisa Watari, Yoshihito Otsuka, Kosei Matsue

Blood (2025) 145 (5): 526–532.

https://doi.org/10.1182/blood.2024026028

Published: 2025

Includes: Supplemental data

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood (2025) 145 (5): 543–546.

https://doi.org/10.1182/blood.2024025868

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood (2025) 145 (3): 300–310.

https://doi.org/10.1182/blood.2024025746

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy

David G. Coffey, Pinar Ataca Atilla, Erden Atilla, Ola Landgren, Andrew J. Cowan, Sylvain Simon, Margot J. Pont, Melissa L. Comstock, Geoffrey R. Hill, Stanley R. Riddell, Damian J. Green

Blood (2025) 145 (2): 220–233.

https://doi.org/10.1182/blood.2024025231

Published: 2025

Includes: Supplemental data

Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood (2025) 145 (2): 202–219.

https://doi.org/10.1182/blood.2024025987

Published: 2025

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri, Sagar Lonial, Brian G. M. Durie, Paul G. Richardson, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2025) 145 (1): 75–84.

https://doi.org/10.1182/blood.2024025939

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Blood (2025) 145 (1): 85–97.

https://doi.org/10.1182/blood.2024025945

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, David Jung, Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, Marios Papadimitriou, Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis

Blood (2024) 144 (25): 2637–2651.

https://doi.org/10.1182/blood.2024026212

Published: 2024

Includes: Supplemental data

Journal Articles

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood (2024) 144 (23): 2432–2438.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood (2024) 144 (23): 2375–2388.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma

Katia Grillone, Serena Ascrizzi, Paolo Cremaschi, Jussara Amato, Nicoletta Polerà, Ottavio Croci, Roberta Rocca, Caterina Riillo, Francesco Conforti, Raffaele Graziano, Diego Brancaccio, Daniele Caracciolo, Stefano Alcaro, Bruno Pagano, Antonio Randazzo, Pierosandro Tagliaferri, Francesco Iorio, Pierfrancesco Tassone

Blood (2024) 144 (16): 1705–1721.

https://doi.org/10.1182/blood.2023021991

Published: 2024

Includes: Supplemental data

Journal Articles

KDM6A regulates immune response genes in multiple myeloma

Daphné Dupéré-Richer, Alberto Riva, Benjamin G. Barwick, Sayantan Maji, Heidi Casellas Román, Jianping Li, Umasankar De, Amin Sobh, Gabrielle Quickstad, Crissandra Piper, Marta Kulis, Teresa Ezponda, José Ignacio Martín-Subero, Giovanni Tonon, Weizhou Zhang, Constantine S. Mitsiades, Lawrence H. Boise, Richard L. Bennett, Jonathan D. Licht

Blood (2024) 144 (14): 1508–1520.

https://doi.org/10.1182/blood.2024024518

Published: 2024

Includes: Supplemental data

Journal Articles

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma

Eve Blanquart, Rüçhan Ekren, Bineta Rigaud, Marie-Véronique Joubert, Virginie Baylot, Hélène Daunes, Marine Cuisinier, Marine Villard, Nadège Carrié, Céline Mazzotti, Liliana E. Lucca, Aurore Perrot, Jill Corre, Thierry Walzer, Hervé Avet-Loiseau, Pierre-Paul Axisa, Ludovic Martinet

Blood (2024) 144 (12): 1271–1283.

https://doi.org/10.1182/blood.2023023529

Published: 2024

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease in a patient with multiple myeloma

Arthur A. Parsee, Julie Y. Li

Blood (2024) 144 (10): 1131.

https://doi.org/10.1182/blood.2024025514

Published: 2024

NARROW

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma

KDM6A regulates immune response genes in multiple myeloma

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma

Erdheim-Chester disease in a patient with multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only